The accident that saved the anus: how anal cancer treatment was reinvented
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Until the 1970s, treatment for anal cancer meant removing the anus and rectum and living with a permanent colostomy. It worked often enough to be standard and it cost people a great deal.
What replaced it came from a surgeon preparing patients for exactly that operation, and discovering the operation was no longer needed.
Related pages: Anal cancer
The bottom line
- Chemoradiation, not surgery, is first-line treatment for most localized anal cancer.
- Most people keep normal bowel function and avoid a permanent colostomy.
- Surgery is reserved for salvage when chemoradiation does not clear the tumour.
- Immunotherapy is used in advanced or recurrent disease.
- How far radiation doses and fields can be reduced without losing cure rates.
- How best to treat disease that recurs after chemoradiation.
The story, step by step
- 1. Before ()
- 2. 1974 ()
- 3. Now ()
- 4. Afterwards ()
- 5. Advanced disease ()
What the evidence labels mean
Radical surgery, and a permanent colostomy
What happens
The standard treatment for most of the twentieth century was abdominoperineal resection.
What the research shows
- The operation removes the anus, rectum and surrounding tissue, and the bowel is brought out through the abdominal wall as a permanent colostomy.
- It cured a proportion of patients and was the only option considered curative.
- The cost was permanent, in body image, function and daily life.
- Radiation alone had been used and gave worse results than surgery at the doses then available.
Why it matters
Knowing what the alternative was makes it clearer why the change that followed was so significant.
What's still uncertain
- Historical survival figures are hard to compare with modern ones because staging methods differed.
Read more
- NCI: Anal cancer treatmentGovernment
Next: 1974
Chemoradiation before surgery, and nothing left to remove
What happens
Norman Nigro, a surgeon in Detroit, set out to shrink tumours before operating.
What the research shows
- He gave a combination of radiation with the chemotherapy drugs 5-fluorouracil and mitomycin C, intending it as preparation for surgery.
- When the first patients went to the operating theatre, the surgical specimens contained no residual tumour.
- The finding was reported in 1974 and was initially met with scepticism.
- Confirmed in larger series and later in randomized trials, it inverted the treatment of the disease: chemoradiation became definitive treatment rather than preparation.
- Anal cancer became one of the first solid tumours routinely cured without removing the organ.
Why it matters
This is one of the clearest organ-preservation stories in oncology, and it began with an observation nobody was looking for.
What's still uncertain
- The original regimen used far lower radiation doses than are used now, and was refined considerably afterwards.
Read more
- NCI: Anal cancer treatmentGovernment
Next: Now
What treatment actually involves
What happens
The modern version of the same approach is more precise and better tolerated.
What the research shows
- Radiation is given as intensity-modulated radiation therapy, IMRT, which shapes the dose around the tumour and spares surrounding tissue.
- Chemotherapy is given at the same time, most often 5-fluorouracil with mitomycin C. Capecitabine, a tablet form, is used in place of intravenous 5-fluorouracil in some regimens.
- Treatment typically runs over five to six weeks.
- Small, early tumours at the anal margin are sometimes treated with local excision alone.
- Most people with localized disease are cured, and most keep normal sphincter function.
Why it matters
Capecitabine replaces the 5-fluorouracil part of the combination, not the mitomycin. Both drugs are still given.
What's still uncertain
- The optimal chemotherapy partner for radiation is still debated in some subgroups.
Read more
- NCI: Anal cancer treatmentGovernment
Next: Afterwards
Response takes time, and side effects are real
What happens
Two things about the aftermath surprise people.
What the research shows
- Tumours continue to shrink for months after treatment ends, so response is assessed over up to six months rather than immediately. A tumour still present at eight weeks is not necessarily treatment failure.
- Acute side effects are significant: skin breakdown in the treated area, diarrhoea, pain, fatigue and low blood counts. These are temporary but demanding.
- Longer-term effects can include bowel urgency and frequency, sexual dysfunction, infertility, early menopause, and rarely pelvic fracture.
- Fertility preservation should be discussed before treatment starts, not after.
- Salvage surgery, abdominoperineal resection, is offered if the cancer persists or returns, and it still cures some people at that point.
Why it matters
The waiting period after treatment is hard and is a normal part of the process rather than a sign that something has gone wrong.
What's still uncertain
- Long-term quality of life data after modern IMRT are still accumulating.
Read more
- NCI: Anal cancer treatmentGovernment
- NCI: Nutrition in cancer careGovernment
Next: Advanced disease
Where immunotherapy comes in
What happens
For cancer that has spread or has returned after chemoradiation, treatment is different.
What the research shows
- First-line treatment for metastatic anal cancer is usually combination chemotherapy.
- PD-1 checkpoint inhibitors such as pembrolizumab and nivolumab are used in advanced or recurrent disease, generally after chemotherapy.
- Response rates to immunotherapy are modest but responses can be durable in those who do respond.
- This is an area where trials are active and where asking about clinical trial options is reasonable.
- Treatment decisions at this stage are highly individual and belong with an oncology team.
Why it matters
The treatment landscape for advanced disease is moving, so what is standard may differ from material written even a few years ago.
What's still uncertain
- Which patients benefit most from checkpoint inhibitors is not yet predictable.
Read more
- NCI: Anal cancer treatmentGovernment
- American Cancer Society: Anal cancerNonprofit